X0306 4 2016-02-05 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001201096 GORMAN KEVIN CHARLES 12780 EL CAMINO REAL SAN DIEGO CA 92130 1 1 0 0 President and CEO Restricted Stock Unit 2016-02-05 5 A 0 E 23000 0.00 A Common Stock 23000 23000 D Stock Option 35.99 2016-02-05 5 A 0 E 109100 0.00 A 2026-02-05 Common Stock 109100 109100 D Restricted Stock Unit 2016-02-05 5 A 0 E 35750 0.00 A 2020-02-05 Common Stock 35750 35750 D Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2017, February 5, 2018, February 5, 2019, and February 5, 2020. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 5, 2016 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Performance Restricted Stock Units ("PRSU") will vest upon the date the Company has achieved both (1) obtaining positive pivotal clinical trial data for the treatment of Tourette syndrome with valbenazine and (2) FDA acceptance of a New Drug Application for the treatment of Tourette syndrome with valbenazine. /s/ Darin Lippoldt, Attorney-In-Fact 2016-02-09